| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Measles (Rubeola) (IgG, IgM) Antibody Panel, IFA, CSF
Test Code70240
CPT Codes
86765 (x2)
Preferred Specimen
1 mL CSF in a sterile leak-proof container
Minimum Volume
0.08 mL
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly icteric
Methodology
Immunofluorescence Assay (IFA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 6 days a week.
Report Available
Reports in 1 day.
Clinical Significance
This panel is used to diagnose persistent rubeola infection of the central nervous system (CNS), a complication of measles in which the virus invades the CNS. Diagnosis of CNS rubeola infection is based on a combination of clinical signs and symptoms, as well as results from various laboratory tests. In addition to testing for measles antibodies in the CSF, evaluating for the presence of CNS rubeola infection (and the specific subtype) may include serum testing for measles, electroencephalography and magnetic resonance imaging studies, and other types of CSF analysis [1].
Subacute sclerosing panencephalitis (SSPE) occurs within 3 to 20 years post-infection in individuals who were infected during the first 2 years of life. Measles-specific antibodies in both serum and CSF are useful defining features of SSPE and measles inclusion body encephalitis (MIBE). Antibody levels are highly elevated in the CSF of SSPE patients and rapidly increase over the course of the disease in patients with MIBE.
Reference
1. Buchanan R, Bonthius DJ. Semin Pediatr Neurol. 2012;19:107-114.
Subacute sclerosing panencephalitis (SSPE) occurs within 3 to 20 years post-infection in individuals who were infected during the first 2 years of life. Measles-specific antibodies in both serum and CSF are useful defining features of SSPE and measles inclusion body encephalitis (MIBE). Antibody levels are highly elevated in the CSF of SSPE patients and rapidly increase over the course of the disease in patients with MIBE.
Reference
1. Buchanan R, Bonthius DJ. Semin Pediatr Neurol. 2012;19:107-114.
